Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer

Kazuho Inoko, Kei Hiraoka, Akihito Inagaki, Mizuna Takahashi, Toshihiro Kushibiki, Koji Hontani, Hironobu Takano, Shoki Sato, Shintaro Takeuchi, Toru Nakamura, Takahiro Tsuchikawa, Toshiaki Shichinohe, Harry E. Gruber, Douglas J. Jolly, Noriyuki Kasahara, Satoshi Hirano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Toca 511, a retroviral replicating vector (RRV) encoding the yeast cytosine deaminase (yCD) prodrug activator gene, which mediates conversion of the prodrug 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU), is currently being evaluated in Phase II/III clinical trials for glioma, and showing highly promising evidence of therapeutic activity. Here we evaluated RRV-mediated prodrug activator gene therapy as a new therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). RRV spread rapidly and conferred significant cytotoxicity with prodrug in a panel of PDAC cells. Efficient intratumoral replication and complete inhibition of tumor growth upon 5-FC administration were observed in both immunodeficient and immunocompetent subcutaneous PDAC models. Biodistribution of RRV was highly restricted in normal tissues, especially in immunocompetent hosts. Tumor growth inhibition by Toca 511 followed by 5-FC was also confirmed in the orthotopic PDAC model. This study provides the first proof-of-concept for application of Toca 511 and Toca FC (extended release 5-FC) to the treatment of human PDAC, and provided support for inclusion of PDAC in a Phase I study evaluating Toca 511 in various systemic malignancies, (NCT02576665), which has recently been initiated.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCancer Gene Therapy
DOIs
StateAccepted/In press - May 8 2018

Fingerprint

Prodrugs
Pancreatic Neoplasms
Genetic Therapy
Flucytosine
Adenocarcinoma
Therapeutics
Cytosine Deaminase
Neoplasms
Phase III Clinical Trials
Phase II Clinical Trials
Growth
Glioma
Fluorouracil
Yeasts
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Inoko, K., Hiraoka, K., Inagaki, A., Takahashi, M., Kushibiki, T., Hontani, K., ... Hirano, S. (Accepted/In press). Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Therapy, 1-12. https://doi.org/10.1038/s41417-018-0020-7

Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. / Inoko, Kazuho; Hiraoka, Kei; Inagaki, Akihito; Takahashi, Mizuna; Kushibiki, Toshihiro; Hontani, Koji; Takano, Hironobu; Sato, Shoki; Takeuchi, Shintaro; Nakamura, Toru; Tsuchikawa, Takahiro; Shichinohe, Toshiaki; Gruber, Harry E.; Jolly, Douglas J.; Kasahara, Noriyuki; Hirano, Satoshi.

In: Cancer Gene Therapy, 08.05.2018, p. 1-12.

Research output: Contribution to journalArticle

Inoko, K, Hiraoka, K, Inagaki, A, Takahashi, M, Kushibiki, T, Hontani, K, Takano, H, Sato, S, Takeuchi, S, Nakamura, T, Tsuchikawa, T, Shichinohe, T, Gruber, HE, Jolly, DJ, Kasahara, N & Hirano, S 2018, 'Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer', Cancer Gene Therapy, pp. 1-12. https://doi.org/10.1038/s41417-018-0020-7
Inoko, Kazuho ; Hiraoka, Kei ; Inagaki, Akihito ; Takahashi, Mizuna ; Kushibiki, Toshihiro ; Hontani, Koji ; Takano, Hironobu ; Sato, Shoki ; Takeuchi, Shintaro ; Nakamura, Toru ; Tsuchikawa, Takahiro ; Shichinohe, Toshiaki ; Gruber, Harry E. ; Jolly, Douglas J. ; Kasahara, Noriyuki ; Hirano, Satoshi. / Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. In: Cancer Gene Therapy. 2018 ; pp. 1-12.
@article{adc9fee1a84c4ca99e128b94ee533bf5,
title = "Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer",
abstract = "Toca 511, a retroviral replicating vector (RRV) encoding the yeast cytosine deaminase (yCD) prodrug activator gene, which mediates conversion of the prodrug 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU), is currently being evaluated in Phase II/III clinical trials for glioma, and showing highly promising evidence of therapeutic activity. Here we evaluated RRV-mediated prodrug activator gene therapy as a new therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). RRV spread rapidly and conferred significant cytotoxicity with prodrug in a panel of PDAC cells. Efficient intratumoral replication and complete inhibition of tumor growth upon 5-FC administration were observed in both immunodeficient and immunocompetent subcutaneous PDAC models. Biodistribution of RRV was highly restricted in normal tissues, especially in immunocompetent hosts. Tumor growth inhibition by Toca 511 followed by 5-FC was also confirmed in the orthotopic PDAC model. This study provides the first proof-of-concept for application of Toca 511 and Toca FC (extended release 5-FC) to the treatment of human PDAC, and provided support for inclusion of PDAC in a Phase I study evaluating Toca 511 in various systemic malignancies, (NCT02576665), which has recently been initiated.",
author = "Kazuho Inoko and Kei Hiraoka and Akihito Inagaki and Mizuna Takahashi and Toshihiro Kushibiki and Koji Hontani and Hironobu Takano and Shoki Sato and Shintaro Takeuchi and Toru Nakamura and Takahiro Tsuchikawa and Toshiaki Shichinohe and Gruber, {Harry E.} and Jolly, {Douglas J.} and Noriyuki Kasahara and Satoshi Hirano",
year = "2018",
month = "5",
day = "8",
doi = "10.1038/s41417-018-0020-7",
language = "English (US)",
pages = "1--12",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer

AU - Inoko, Kazuho

AU - Hiraoka, Kei

AU - Inagaki, Akihito

AU - Takahashi, Mizuna

AU - Kushibiki, Toshihiro

AU - Hontani, Koji

AU - Takano, Hironobu

AU - Sato, Shoki

AU - Takeuchi, Shintaro

AU - Nakamura, Toru

AU - Tsuchikawa, Takahiro

AU - Shichinohe, Toshiaki

AU - Gruber, Harry E.

AU - Jolly, Douglas J.

AU - Kasahara, Noriyuki

AU - Hirano, Satoshi

PY - 2018/5/8

Y1 - 2018/5/8

N2 - Toca 511, a retroviral replicating vector (RRV) encoding the yeast cytosine deaminase (yCD) prodrug activator gene, which mediates conversion of the prodrug 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU), is currently being evaluated in Phase II/III clinical trials for glioma, and showing highly promising evidence of therapeutic activity. Here we evaluated RRV-mediated prodrug activator gene therapy as a new therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). RRV spread rapidly and conferred significant cytotoxicity with prodrug in a panel of PDAC cells. Efficient intratumoral replication and complete inhibition of tumor growth upon 5-FC administration were observed in both immunodeficient and immunocompetent subcutaneous PDAC models. Biodistribution of RRV was highly restricted in normal tissues, especially in immunocompetent hosts. Tumor growth inhibition by Toca 511 followed by 5-FC was also confirmed in the orthotopic PDAC model. This study provides the first proof-of-concept for application of Toca 511 and Toca FC (extended release 5-FC) to the treatment of human PDAC, and provided support for inclusion of PDAC in a Phase I study evaluating Toca 511 in various systemic malignancies, (NCT02576665), which has recently been initiated.

AB - Toca 511, a retroviral replicating vector (RRV) encoding the yeast cytosine deaminase (yCD) prodrug activator gene, which mediates conversion of the prodrug 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU), is currently being evaluated in Phase II/III clinical trials for glioma, and showing highly promising evidence of therapeutic activity. Here we evaluated RRV-mediated prodrug activator gene therapy as a new therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). RRV spread rapidly and conferred significant cytotoxicity with prodrug in a panel of PDAC cells. Efficient intratumoral replication and complete inhibition of tumor growth upon 5-FC administration were observed in both immunodeficient and immunocompetent subcutaneous PDAC models. Biodistribution of RRV was highly restricted in normal tissues, especially in immunocompetent hosts. Tumor growth inhibition by Toca 511 followed by 5-FC was also confirmed in the orthotopic PDAC model. This study provides the first proof-of-concept for application of Toca 511 and Toca FC (extended release 5-FC) to the treatment of human PDAC, and provided support for inclusion of PDAC in a Phase I study evaluating Toca 511 in various systemic malignancies, (NCT02576665), which has recently been initiated.

UR - http://www.scopus.com/inward/record.url?scp=85046534791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046534791&partnerID=8YFLogxK

U2 - 10.1038/s41417-018-0020-7

DO - 10.1038/s41417-018-0020-7

M3 - Article

SP - 1

EP - 12

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

ER -